Premium
Capnocytophaga in the dental plaque of immunocompromised children with cancer
Author(s) -
SIXOU J. L.,
AUBRYLEULIETTE A.,
DE MEDEIROSBATTISTA O.,
LEJEUNE S.,
JOLIVETGOUGEON A.,
SOLHIPINSARD H.,
GANDEMER V.,
BARBOSAROGIER M.,
BONNAUREMALLET M.
Publication year - 2006
Publication title -
international journal of paediatric dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.183
H-Index - 62
eISSN - 1365-263X
pISSN - 0960-7439
DOI - 10.1111/j.1365-263x.2006.00697.x
Subject(s) - capnocytophaga , medicine , antibiotics , anaerobic exercise , cancer , imipenem , microbiology and biotechnology , gastroenterology , bacteria , physiology , biology , antibiotic resistance , genetics
Summary. Objectives. (i) To compare the prevalence and levels of Capnocytophaga , a known systemic pathogen in immunocompromised patients, in the dental plaque of healthy children and children with cancer, and (ii) to determine the susceptibility of strains isolated from cancer patients to a range of antibiotics. Patients and methods. Thirty‐one children with cancer undergoing a first course of immunosuppressive chemotherapy and 30 healthy control children were included in the study. Samples were collected on days 0, 7, 14, and 21 of the cure (and equivalent dates in controls). Susceptibility to antibiotics was tested using an agar dilution method and galleries with predefined concentrations of selected antibiotics. Results. There was a significant drop in the total anaerobic cultivable flora on day 14 and in the prevalence of Capnocytophaga on days 14 and 21 in the children with cancer. The proportion of Capnocytophaga in the anaerobic flora, however, was high in certain cancer patients. Beta‐lactam/beta‐lactamase inhibitor combinations, imipenem, clindamycin, and tetracycline were the most effective against Capnocytophaga . Conclusion. This study showed that Capnocytophaga decreased in prevalence and proportion in the dental plaque of cancer patients during chemotherapy but became predominant in some cases. It is recommended that imipenem or beta‐lactam/beta‐lactamase inhibitor combinations be used to treat Capnocytophaga bacteraemia.